Literature DB >> 11339158

Hypoglycemia and the breastfed neonate.

A I Eidelman1.   

Abstract

Healthy, full-term infants are functionally and metabolically programmed to make the transition from their intrauterine dependent environment to their extrauterine existence without the need for metabolic monitoring or interference with the natural breastfeeding process. Full-term infants are equipped with homeostatic mechanisms that preserve adequate energy substrate to the brain and other vital organs. Thermal stability and early, properly guided, frequent, exclusive breastfeeding are the keys to success. Thus, routine screening for blood glucose concentrations or feeding sugar water is not necessary and potentially counterproductive to the establishment of a healthy mother-infant dyad.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11339158     DOI: 10.1016/s0031-3955(08)70031-2

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  4 in total

1.  Plasma glucose levels in term infants who are appropriate size for gestation and exclusively breast fed.

Authors:  K K Diwakar; M V Sasidhar
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-07       Impact factor: 5.747

2.  ABM clinical protocol #1: guidelines for blood glucose monitoring and treatment of hypoglycemia in term and late-preterm neonates, revised 2014.

Authors:  Nancy Wight; Kathleen A Marinelli
Journal:  Breastfeed Med       Date:  2014-05       Impact factor: 1.817

3.  Study of Asymptomatic Hypoglycemia in Full Term Exclusively Breastfed Neonates in First 48 Hours of Life.

Authors:  Purnima Samayam; Pradeep Krishna Ranganathan; Usha Deepthi Kotari; Ravichander Balasundaram
Journal:  J Clin Diagn Res       Date:  2015-09-01

Review 4.  Neonatal Hypoglycemia and Brain Vulnerability.

Authors:  Laura Costanza De Angelis; Giorgia Brigati; Giulia Polleri; Mariya Malova; Alessandro Parodi; Diego Minghetti; Andrea Rossi; Paolo Massirio; Cristina Traggiai; Mohamad Maghnie; Luca Antonio Ramenghi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-16       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.